partner with us

Developing best in class therapies for rare diseases

Potential partners

NovelMed is a proven leader in the field of rare diseases that are complement-mediated. At NovelMed, we are continuously encouraged by the needs of patients as we discover game-changing therapies for rare diseases. Every rare disease is unique but the treatment may be similar as they all may fall under a difinite class of diseases to be treated by the same drug. Such opportunities are limited for the discoverers and developers. At NovelMed, we combine scientific and clinical expertise in developing new therapies for rare diseases of the complement system so that we can rapidly move new drugs for rare diseases with limited or no treatment options not only suitable for one but for many indications driven by the similar mechanism of action.
NovelMed has a robust product driven technology capable of producing a proprietary pipeline of novel therapeutics & diagnostic monoclonal antibodies to diagnose and treat rare diseases. Our lead product candidate, NM8074, is a first-in-class, anti-Bb antibody that selectively targets the alternative pathway of the Complement system. This novel antibody drug is moving towards clinical development for the treatment of rare diseases specially in hematology, ocular, and inflammatory disorders. Because numerous rare diseases are driven by the same underlying mechanism treatable by NM8074, there are clear possibilities for therapeutic intervention for other indications categorized under unmet need.
We are very interested in licensing our drugs to a partner for their development as novel therapies for rare diseases.

Upcoming milestones & long term priorities

While our lead compound is currently in large scale production, or major objectives are to:

Locate the right pharmaceutical / biotech partners to help us carry our years of successful development to commercialization.

Receive orphan and breakthrough status in several of our priority clinical indications.

Help initiate clinical trial programs in our leading inflammatory-mediated disease states.